ginseng, Ontario

Reported Uses

• NOTE: see Herb & Supplement Effectiveness Rating Definitions table
• ADHD [Insufficient Evidence]
• anemia, chronic dz-related [Insufficient Evidence]
• antiretroviral-induced insulin resistance [Insufficient Evidence]
• athletic performance [Insufficient Evidence]
• breast CA [Insufficient Evidence]
• cancer-related fatigue [Insufficient Evidence]
• cardiovascular dz [Insufficient Evidence]
• cognitive function [Insufficient Evidence]
• diabetes mellitus, type 2 [Insufficient Evidence]
• epilepsy [Insufficient Evidence]
• headache [Insufficient Evidence]
• HIV/AIDS [Insufficient Evidence]
• HTN [Insufficient Evidence]
• menopausal sx [Insufficient Evidence]
• schizophrenia [Insufficient Evidence]
• ulcerative colitis [Insufficient Evidence]
• URI [Possibly Effective]

Reported Doses

Safety/efficacy may not be established; reported doses may be derived from limited or potentially inadequate studies w/ variable regimens, multi-ingredient products, or where concentration of active ingredients may vary widely

Special Note, COVID-19

[no scientific data for COVID-19]

Info: see Herb & Supplement Remedy Use in COVID-19 Resources

Special Note

[formulation clarification]

Info: extracts generally stdzd to 0.052-11.65% ginsenoside content

Effectiveness Ratings

[see Herb & Supplement Effectiveness Rating Definitions table]

ADHD, peds pts

[Insufficient Evidence]

Dose: 200 mg PO bid; Info: for pts 3-17 yo; used w/ ginkgo

cancer-related fatigue

[Insufficient Evidence]

Dose: 1 g PO bid

cognitive function

[Insufficient Evidence]

Dose: 100-400 mg PO x1; Alt: 200 mg PO qd

diabetes mellitus, type 2

[Insufficient Evidence]

Dose: 3 g PO x1 up to 2h before a meal; Alt: 1.5 g PO qd; Info: used w/ or w/o Asian ginseng

HTN

[Insufficient Evidence]

Dose: 0.5-1 g PO tid; Info: used w/ or w/o Asian ginseng

menopausal sx

[Insufficient Evidence]

Dose: 50 mg PO bid

schizophrenia

[Insufficient Evidence]

Dose: 100 mg PO bid

URI

[Possibly Effective]

Dose: 200-400 mg PO bid